ARTICLE | Strategy
Horizons beyond Horizant
Neurology play XenoPort turns corner now that Horizant approved for RLS
May 23, 2011 7:00 AM UTC
See related article: For want of a nail
XenoPort Inc. paid a heavy price for regulatory delays for Horizant gabapentin enacarbil to treat restless legs syndrome. But now the biotech has come out the other side with a clear focus on neurology and ambitions to graduate from an R&D shop to a commercial enterprise...